about
Computational Approaches to Toll-Like Receptor 4 ModulationComparative Geometrical Analysis of Leucine-Rich Repeat Structures in the Nod-Like and Toll-Like Receptors in Vertebrate Innate Immunity.Identifying novel spatiotemporal regulators of innate immunityTyrosine phosphorylation in Toll-like receptor signalingThe Yin and Yang of Toll-like receptors in cancerInterferon induction by RNA viruses and antagonism by viral pathogensToll-like receptors in systemic lupus erythematosus: potential targets for therapeutic interventionGraft rejection - endogenous or allogeneic?Targeting Toll-like receptors with small molecule agentsMultiple roles of toll-like receptor 4 in colorectal cancerTargeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseasesToll-like receptors in antiviral innate immunityPhagocytosed Clofazimine Biocrystals Can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA SecretionStimulation of host immune defenses by a small molecule protects C. elegans from bacterial infectionTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyDeubiquitinases: Novel Therapeutic Targets in Immune Surveillance?APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectivePathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusProgress toward in vivo use of siRNAs-IIHistone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophagesIn vitro inflammation inhibition model based on semi-continuous toll-like receptor biosensingInduction of interferon-stimulated genes by IRF3 promotes replication of Toxoplasma gondiiLL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAsPIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signalingIs Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis.The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.T granules in human platelets function in TLR9 organization and signaling.Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbiditiesImproved HSC reconstitution and protection from inflammatory stress and chemotherapy in mice lacking granzyme B.Proteome and Secretome Analysis Reveals Differential Post-transcriptional Regulation of Toll-like Receptor Responses.Toll-like receptor mediated regulation of breast cancer: a case of mixed blessings.Mechanisms of inflammatory responses in obese adipose tissue.The Toll-like receptor gene family is integrated into human DNA damage and p53 networks.Trial Watch: Toll-like receptor agonists in oncological indications.Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier functionPreliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis.Chemiluminometric immuno-analysis of innate immune response against repetitive bacterial stimulations for the same mammalian cells.Humanized TLR7/8 expression drives proliferative multisystemic histiocytosis in C57BL/6 mice.Sex Differences in monocytes and TLR4 associated immune responses; implications for systemic lupus erythematosus (SLE)
P2860
Q26740008-58B82205-E394-4F99-806B-ADDDD07F83D8Q26795777-524628C0-EECD-435A-9C2C-8C20E8610A27Q26823854-53F49D60-E963-4E2F-8C87-189BE2C38959Q26828015-DE1EC17C-74B6-4281-B5B2-639862180F8EQ26851526-DB698164-1B2E-4E6F-A507-0DF13519E995Q26860007-1D1D39CE-88AF-4911-8543-6A4BD407F7C3Q26865485-87C85BED-9422-48A3-9CF9-6F4E96D69004Q26866523-E996B412-7285-475A-9AF9-0910B5B047A6Q26992220-6198AF85-03EF-4F23-8685-D406F2111229Q27008380-154DF535-8F30-470B-A91A-E9CF0A38ADF7Q27010345-1E6162A0-DFD5-40FD-BFB2-32C4526E5093Q27011462-1E32FC98-4D08-4B70-809D-0D0759D6F6EDQ27301088-CAC454F7-BB2D-4604-AFFC-051903A2169EQ27333654-481B2621-C2AF-4502-BE24-910A39ACA7D6Q28067939-6109D934-8FE6-4632-95AF-6172F9B46236Q28069021-D4992892-B441-499E-B743-8FCE655689F7Q28085213-B8E548C3-6829-4657-92A7-E8C2462BAA70Q28088753-3DF347D3-DDE3-4861-83F8-120049C36AF0Q28255877-5D56D442-82DD-4FAA-AA2C-85D47A6EC0B6Q28294510-BECE4BC3-2D39-4C54-BD9C-8ADFA3D031FBQ28542384-B706EF4C-474B-480C-9F91-3D386DF67C7DQ28545027-E53D6C20-5870-4333-95D3-6BA257159F31Q28743558-FF336A5A-E63D-4DA9-81D5-0DD9E01A8A69Q28833590-425C50B3-8630-4028-BC9F-88E53A288F42Q30388063-549A6E19-4525-41B9-B9B0-DB98B6BD3F0FQ30486741-2750744C-BF8F-4C4C-A4A3-A7AB88D57A80Q30528922-2711EBEB-0C91-49F5-8AF6-56B7343BAF78Q31142266-008E7D86-E9A7-4F68-A079-8CB7A50893BBQ33569831-66186EE1-1194-41DF-BC7F-D4F8460B381AQ33569840-DA7D26E9-43D5-48D7-8FD8-6122C83A29E8Q33658124-7EA95C77-3E37-485E-A2B2-B76572BB88C8Q33699810-1841AE61-8730-444A-B079-E6241BFD43BAQ33869489-8D79A2E3-3288-4FEA-8CDC-187BB156EBF2Q33878578-D2F19921-5CAA-4A75-BCC5-F21F11BA5D18Q33899677-CD123CF3-E9B4-48D4-B120-867580A2A04EQ33914745-F770D876-6687-47B3-80FF-FE82492C7EB0Q34016661-D95F900A-279E-431D-88A7-385834EE2937Q34023292-398299FD-2F0E-4E97-A8A2-A390B3275D65Q34208023-E1406561-BDAC-4B93-9DDE-4D60042A90E7Q34323715-30622510-6F62-457B-9BBE-02AD4D14055A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting Toll-like receptors: emerging therapeutics?
@en
Targeting Toll-like receptors: emerging therapeutics?
@nl
type
label
Targeting Toll-like receptors: emerging therapeutics?
@en
Targeting Toll-like receptors: emerging therapeutics?
@nl
prefLabel
Targeting Toll-like receptors: emerging therapeutics?
@en
Targeting Toll-like receptors: emerging therapeutics?
@nl
P356
P1476
Targeting Toll-like receptors: emerging therapeutics?
@en
P2093
Andrew E Parker
Elizabeth J Hennessy
P2888
P304
P356
10.1038/NRD3203
P577
2010-04-01T00:00:00Z